Cellectis SA
USUSDCellectis SA (US:CMVLF) — Biotechnology: Pharmaceutical Preparations. Брой борси, на които се търгуват акциите на компанията: 3. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За Компанията
- Уебсайт
- cellectis.com
- Връзки с Инвеститорите
- cellectis.com/en/investors/governance/
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Централа
- France, France
- Изпълнителен Директор
- Andre Choulika
- Служители
- 224
- Основана
- 1999
- Акции в Обращение
- 72.72 млн
- Свободно Търгуеми Акции
- 48.58 млн
- Пазарна Капитализация
- 148.06 млн USD
- Инсайдери
- 0%
- Институционални Инвеститори
- 15.36%
- Отрасъл (SIC)
- Biological Products, (No Diagnostic Substances)
- Правна Форма
- QVPB
- ISIN
- FR0010425595
- LEI
- 5493000KKX5VQ37Q2W83
- FCF
- −41.8 млн USD
- Дълг
- ?
- Печалби и FCF — за 12-те месеца до 31.12.2025 (последният доклад на компанията).
- NAV
Описание
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Най-Големи Притежатели
| Притежател | Дял | Акции | Дата на Доклада |
|---|---|---|---|
| B Group, Inc. | 4.55% | 3.28 млн | 2026-06-30 |
| Long Focus Capital Manag… | 3.8% | 2.74 млн | 2026-06-30 |
| UBS AM, a distinct busin… | 3.67% | 2.64 млн | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.33% | 235 696 | 2026-08-31 |
| Nomura Asset Management… | 0.31% | 226 875 | 2026-06-30 |
| Delaware Group Equity Fu… | 0.31% | 226 875 | 2026-06-30 |
| Blackrock Inc. | 0.31% | 225 444 | 2026-06-30 |
| Morgan Stanley | 0.12% | 85 455 | 2026-06-30 |
| LPL Financial LLC | 0.12% | 84 415 | 2026-06-30 |
| Susquehanna Internationa… | 0.07% | 50 453 | 2026-06-30 |
| BNP Paribas Financial Ma… | 0.06% | 40 100 | 2026-06-30 |
| UBS Group AG | 0.05% | 33 926 | 2026-06-30 |
| Fidelity Concord Street… | 0% | 1 949 | 2026-07-31 |
